Biotech entity
pharma is the sole category represented across all 1 tracked stories. U.S. Department of the Interior is most often covered alongside Antonin Scalia, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention U.S. Department of the Interior, all published on July 15, 2026.
Last mentioned: Jul 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. U.S. Department of the Interior is most often covered alongside Antonin Scalia, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention U.S. Department of the Interior, all published on July 15, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Department of the Interior. Shared-story counts are live from our verified record — not editorial picks.
The rescission of the ESA's 'harm' definition removes a major regulatory hurdle for biotech and pharma facility construction near sensitive habitats. Starting September 12, 2026, indirect habitat impacts will no longer trigger 'take' liability, potentially accelerating project timelines and reducing permitting costs for life-science companies.
U.S. Department of the Interior is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
